- Jun 6, 2005
I agree...each of us must arrive at our own conclusions. The following 2 articles offer dissimilar views.Everyone needs to take their own decision, but personally I think I'll wait: as Gracielle posted on the previous page, these vaccines are the original ones developed for COVID, not the bivalent ones starting to be used in Europe now. ...
3 October 2022 by Stephani Desmond
Combining proteins from two SARS-CoV-2 variants, bivalent booster shots protect against the currently circulating BA.5 subvariant—and may afford longer-lasting immunity.
This article is protected by a paywall. I am posting 90% of it which, in my opinion, is relevant to this topic.
25 October 2022 by Robert Langreth
(Bloomberg) -- Bivalent booster shots from Moderna Inc. and Pfizer Inc. failed to raise levels of protective proteins called neutralizing antibodies against the dominant omicron strains any more than four doses of the original Covid vaccine, according to an early independent study on a small...
Three to five weeks after a fourth shot, those people who received the new boosters aimed at BA.4 and BA.5 variants “had similar neutralizing antibody titers as those receiving a fourth monovalent mRNA vaccine,” the authors conclude in a manuscript posted on the preprint server bioRxiv.org. This held true for antibodies that protect against BA.4, BA.5 and older variants such as the original omicron strain, according to the study....The results don’t mean that getting a bivalent shot has no benefit, and it will need to be confirmed in much larger studies. However, they raise the question of whether the switch to a new version of the vaccine was necessary....
....In early October, Moderna researchers published data from the clinical trial of a different bivalent booster that is tailored to the original omicron strain. That study, in the New England Journal of Medicine, found that a fourth shot of that bivalent vaccine produced higher levels of antibodies compared to four shots of Moderna’s original vaccine. Moderna’s bivalent vaccine against the original omicron strain, called mRNA-1273.214, is not authorized in the U.S., but has been cleared for use in numerous countries including the UK and Canada. Nonetheless, scientists have harbored doubts about the benefit of switching up the shots’ composition. Before the US began rolling out updated boosters in September, John Moore, a professor of microbiology and immunology at Weill Cornell Medical College said the new vaccines would be “little or no better” than earlier formulations.